LTC3653227I2 - - Google Patents

Info

Publication number
LTC3653227I2
LTC3653227I2 LTPA2022506C LTPA2022506C LTC3653227I2 LT C3653227 I2 LTC3653227 I2 LT C3653227I2 LT PA2022506 C LTPA2022506 C LT PA2022506C LT PA2022506 C LTPA2022506 C LT PA2022506C LT C3653227 I2 LTC3653227 I2 LT C3653227I2
Authority
LT
Lithuania
Application number
LTPA2022506C
Other languages
Lithuanian (lt)
Original Assignee
Ascendis Pharma Endocrinology Division A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC3653227(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Endocrinology Division A/S filed Critical Ascendis Pharma Endocrinology Division A/S
Publication of LTPA2022506I1 publication Critical patent/LTPA2022506I1/lt
Publication of LTC3653227I2 publication Critical patent/LTC3653227I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005—Cultivation methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00—Vegetative propagation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06—Epoxy-capping

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Forests & Forestry (AREA)
  • Ecology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTPA2022506C 2014-11-18 2022-05-23 LTC3653227I2 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
PCT/EP2015/076813 WO2016079114A1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs
EP15797642.4A EP3237014B1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (2)

Publication Number Publication Date
LTPA2022506I1 LTPA2022506I1 (cg-RX-API-DMAC7.html) 2022-06-10
LTC3653227I2 true LTC3653227I2 (cg-RX-API-DMAC7.html) 2024-11-25

Family

ID=51951624

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19214864.1T LT3653227T (lt) 2014-11-18 2015-11-17 Nauji polimeriniai hgh provaistai
LTPA2022506C LTC3653227I2 (cg-RX-API-DMAC7.html) 2014-11-18 2022-05-23

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP19214864.1T LT3653227T (lt) 2014-11-18 2015-11-17 Nauji polimeriniai hgh provaistai

Country Status (27)

Country Link
US (3) US10799563B2 (cg-RX-API-DMAC7.html)
EP (3) EP3653227B9 (cg-RX-API-DMAC7.html)
JP (6) JP6783782B2 (cg-RX-API-DMAC7.html)
KR (3) KR102608645B1 (cg-RX-API-DMAC7.html)
AU (3) AU2015348633C1 (cg-RX-API-DMAC7.html)
CA (2) CA2968282C (cg-RX-API-DMAC7.html)
CY (2) CY1123963T1 (cg-RX-API-DMAC7.html)
DK (2) DK3653227T5 (cg-RX-API-DMAC7.html)
ES (2) ES2864415T7 (cg-RX-API-DMAC7.html)
FI (2) FI3237014T3 (cg-RX-API-DMAC7.html)
FR (1) FR22C1029I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20210400T4 (cg-RX-API-DMAC7.html)
HU (2) HUE053855T2 (cg-RX-API-DMAC7.html)
IL (3) IL326263A (cg-RX-API-DMAC7.html)
LT (2) LT3653227T (cg-RX-API-DMAC7.html)
LU (1) LUC00256I2 (cg-RX-API-DMAC7.html)
MX (2) MX394222B (cg-RX-API-DMAC7.html)
NL (1) NL301172I2 (cg-RX-API-DMAC7.html)
NO (1) NO2022014I1 (cg-RX-API-DMAC7.html)
PL (1) PL3653227T6 (cg-RX-API-DMAC7.html)
PT (1) PT3653227T (cg-RX-API-DMAC7.html)
RS (1) RS61734B2 (cg-RX-API-DMAC7.html)
RU (1) RU2718664C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201703870UA (cg-RX-API-DMAC7.html)
SI (1) SI3653227T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100172T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016079114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
EP4732848A3 (en) * 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
RU2768747C2 (ru) * 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CA3093083A1 (en) * 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
US12565525B2 (en) 2018-03-28 2026-03-03 Ascendis Pharma Oncology Division A/S IL-2 conjugates
SG11202104966XA (en) 2019-01-04 2021-06-29 Ascendis Pharma Oncology Div A/S Sustained local drug levels for innate immune agonists
AU2020205029A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
SG11202105835YA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
JP7524206B2 (ja) * 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
EP4314035A1 (en) * 2021-04-01 2024-02-07 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
CA3237877A1 (en) * 2021-11-12 2023-05-19 Aditya JARARE Novel formulation for drying of polymer dye conjugated antibodies

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL78930A0 (en) 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
JPH0531189A (ja) 1991-01-16 1993-02-09 Takeda Chem Ind Ltd 2室型注射器
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
SE501808C2 (sv) 1993-11-26 1995-05-22 Hans Lundstroem Anordning vid en box
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
OA13063A (en) 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
MXPA05005178A (es) 2002-11-15 2005-07-22 Hoffmann La Roche Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).
US20040142870A1 (en) 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005035553A2 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
EP1579873A1 (en) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
BRPI0611570A2 (pt) 2005-06-15 2011-02-22 Novo Nordisk Healthcare Ag métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2007114881A1 (en) 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
WO2011003234A1 (zh) 2009-07-08 2011-01-13 深圳市掌网立体时代视讯技术有限公司 光学立体放映装置、系统及方法
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
EP2512450B1 (en) * 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
DK2571510T3 (en) 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
WO2014060512A1 (en) 2012-10-17 2014-04-24 Novo Nordisk Health Care Ag Fatty acid acylated amino acids for growth hormone delivery
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016109823A1 (en) 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形

Also Published As

Publication number Publication date
DK3237014T5 (da) 2024-10-14
JP7785109B2 (ja) 2025-12-12
LT3653227T (lt) 2021-03-25
JP2024054177A (ja) 2024-04-16
EP4218823A2 (en) 2023-08-02
US20200390864A1 (en) 2020-12-17
EP4218823A3 (en) 2023-11-15
FR22C1029I1 (fr) 2022-09-09
MX394222B (es) 2025-03-24
AU2024201227A1 (en) 2024-03-28
MX2022009155A (es) 2022-08-16
IL251906B2 (en) 2024-04-01
RS61734B2 (sr) 2022-04-29
KR20170084267A (ko) 2017-07-19
KR20250059541A (ko) 2025-05-02
NL301172I1 (nl) 2022-04-29
PL3653227T6 (pl) 2022-04-19
AU2015348633B2 (en) 2020-10-22
US20170354716A1 (en) 2017-12-14
JP6783782B2 (ja) 2020-11-11
RS61734B1 (sr) 2021-05-31
EP3653227B1 (en) 2021-01-20
CA3294730A1 (en) 2026-03-02
NZ769682A (en) 2024-09-27
JP7210683B2 (ja) 2023-01-23
HUS2200019I1 (hu) 2022-06-28
EP3237014B1 (en) 2023-03-29
IL307773B1 (en) 2026-03-01
HUE053855T2 (hu) 2021-07-28
US20250032587A1 (en) 2025-01-30
DK3653227T5 (da) 2023-08-21
ES2864415T7 (es) 2022-05-12
HRP20210400T4 (hr) 2022-04-29
NL301172I2 (nl) 2022-06-16
SMT202100172T1 (it) 2021-05-07
US10799563B2 (en) 2020-10-13
RU2718664C2 (ru) 2020-04-13
HRP20210400T1 (hr) 2021-04-16
EP3237014A1 (en) 2017-11-01
LTPA2022506I1 (cg-RX-API-DMAC7.html) 2022-06-10
CA2968282C (en) 2026-06-09
CA2968282A1 (en) 2016-05-26
CY2022013I2 (el) 2023-01-05
EP3653227A1 (en) 2020-05-20
ES2947818T3 (es) 2023-08-21
AU2015348633C1 (en) 2021-02-11
NO2022014I1 (no) 2022-05-12
RU2017121203A3 (cg-RX-API-DMAC7.html) 2019-05-30
ES2864415T9 (es) 2023-05-23
WO2016079114A1 (en) 2016-05-26
BR112017009798A8 (pt) 2020-11-03
US12133883B2 (en) 2024-11-05
AU2020270494B2 (en) 2024-02-01
PT3653227T (pt) 2021-02-26
IL307773B2 (en) 2026-07-01
NZ731779A (en) 2021-11-26
LUC00256I2 (cg-RX-API-DMAC7.html) 2025-03-04
JP2021020932A (ja) 2021-02-18
RU2017121203A (ru) 2018-12-19
ES2864415T3 (es) 2021-10-13
JP6982156B2 (ja) 2021-12-17
JP7431355B2 (ja) 2024-02-14
JP2017535609A (ja) 2017-11-30
FIC20220017I1 (fi) 2022-06-03
JP2026041857A (ja) 2026-03-10
DK3653227T6 (da) 2022-04-11
SG10202105511RA (en) 2021-07-29
PL3653227T3 (pl) 2021-07-05
IL307773A (en) 2023-12-01
CY2022013I1 (el) 2023-01-05
IL326263A (en) 2026-03-01
JP2022033787A (ja) 2022-03-02
IL251906A0 (en) 2017-06-29
SI3653227T1 (sl) 2021-04-30
DK3653227T3 (da) 2021-02-15
SG11201703870UA (en) 2017-06-29
MX2017006113A (es) 2017-10-16
AU2020270494A1 (en) 2020-12-17
FI3237014T3 (fi) 2023-06-09
CY1123963T1 (el) 2022-05-27
FR22C1029I2 (fr) 2023-04-14
KR20230152187A (ko) 2023-11-02
AU2015348633A1 (en) 2017-05-18
EP3653227B3 (en) 2022-03-09
DK3237014T3 (da) 2023-05-30
EP3653227B9 (en) 2023-03-08
KR102608645B1 (ko) 2023-12-01
IL251906B1 (en) 2023-12-01
BR112017009798A2 (pt) 2017-12-19
JP2023052300A (ja) 2023-04-11

Similar Documents

Publication Publication Date Title
BR112016017664A2 (cg-RX-API-DMAC7.html)
BR112016016761A2 (cg-RX-API-DMAC7.html)
BR112016015519A2 (cg-RX-API-DMAC7.html)
BR112016003131A2 (cg-RX-API-DMAC7.html)
BR112016016546A2 (cg-RX-API-DMAC7.html)
BR112016014949A2 (cg-RX-API-DMAC7.html)
BR112016017103A2 (cg-RX-API-DMAC7.html)
BR112016016612A2 (cg-RX-API-DMAC7.html)
BR112016017031A2 (cg-RX-API-DMAC7.html)
BR112016016924A2 (cg-RX-API-DMAC7.html)
BR112015027867A2 (cg-RX-API-DMAC7.html)
BR112016016421A2 (cg-RX-API-DMAC7.html)
BR112016016558A2 (cg-RX-API-DMAC7.html)
BR112016017960A2 (cg-RX-API-DMAC7.html)
BR112016015915A2 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016016468A2 (cg-RX-API-DMAC7.html)
BR112016017356A2 (cg-RX-API-DMAC7.html)
BR112016016459A2 (cg-RX-API-DMAC7.html)
BR112016003522A2 (cg-RX-API-DMAC7.html)
BR112016017375A2 (cg-RX-API-DMAC7.html)
BR112016014482A2 (cg-RX-API-DMAC7.html)
BR112016017135A2 (cg-RX-API-DMAC7.html)
BR112016015054A2 (cg-RX-API-DMAC7.html)
BR112016017675A2 (cg-RX-API-DMAC7.html)